Braftide Polypeptide Disrupts BRAF Dimerization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current BRAF inhibitors, such as dabrafenib and vemurafenib, are limited in efficacy as they stimulate paradoxical activation in tumor cells with wild-type BRAF and oncogenic RAS, and exhibit drug resistance in non-V600 BRAF mutations, necessitating the development of alternative therapeutic strategies for cancer treatment.
Innovation Solution
The use of a polypeptide, braftide, which targets the dimer interface of BRAF kinase to disrupt dimerization, thereby inhibiting BRAF kinase activity and abrogating hyperactivated MAPK signaling, is proposed. Braftide is designed to inhibit both BRAF homodimers and heterodimers, including those resistant to existing inhibitors, by binding to the dimer interface and triggering proteasome-mediated degradation of BRAF and MEK.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ATP-competitive inhibitors (dabrafenib and vemurafenib) are used to inhibit BRAFV600E, then response rates in melanoma patients are improved, but paradoxical activation occurs in tumor cells with wild-type BRAF and oncogenic RAS
Solution Approach 1:
Instead of using ATP-competitive inhibitors that bind to the active site and can cause paradoxical activation, the patent employs allosteric inhibitors that bind to a different site on BRAF. This inverted approach of targeting an alternative location eliminates the harmful paradoxical activation while preserving the desired inhibition of oncogenic BRAF signaling.
Solution Approach 2:
The patent introduces a novel allosteric inhibitor as an intermediary substance that mediates inhibition of BRAF kinase activity without triggering paradoxical activation. This intermediary compound serves as a bridge between the therapeutic goal of inhibiting BRAF and the constraint of avoiding harmful effects in wild-type tumors.
2Reliability
If ATP-competitive inhibitors are used to target BRAFV600E, then efficacy in BRAFV600E tumors is improved, but intrinsic drug resistance occurs in non-V600 BRAF mutations
Solution Approach 1:
The allosteric inhibitor developed in the patent exhibits universal activity across multiple BRAF mutation types including BRAFV600E, BRAFG469A, and other non-V600 mutations. This multi-functional capability allows a single therapeutic agent to address diverse oncogenic BRAF variants that previously required different treatments.
Solution Approach 2:
The patent employs a different inhibition mechanism (allosteric binding) with distinct biochemical parameters compared to ATP-competitive inhibitors. This parameter change in the mode of action enables the drug to effectively bind and inhibit various BRAF mutants that are resistant to conventional ATP-competitive inhibitors.
3Reliability
If ATP-competitive inhibitors are used, then inhibition of BRAFV600E kinase activity is achieved, but secondary malignancies are induced due to pathway stimulation in wild-type BRAF tumors
Solution Approach 1:
The patent inverts the therapeutic approach by using allosteric inhibition instead of ATP-competitive inhibition. This inverted strategy achieves the beneficial effect of suppressing oncogenic BRAF signaling while avoiding the harmful paradoxical activation that leads to secondary malignancies.
Solution Approach 2:
The patent converts the limitation of allosteric binding (lower affinity compared to ATP-competitive binding) into a benefit by selecting an allosteric site that, when occupied, prevents paradoxical activation. The apparent weakness becomes a therapeutic advantage by eliminating the harmful pathway stimulation in wild-type tumors.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Braftide effectively inhibits BRAF kinase activity, reduces MAPK signaling, and induces apoptosis in cancer cells with minimal impact on non-cancerous cells, overcoming the limitations of existing BRAF inhibitors by preventing paradoxical activation and drug resistance, thus offering a broader therapeutic spectrum for cancers with non-V600 BRAF mutations and RAS mutations.
Implementation Method 1
Braftide is designed to inhibit both BRAF homodimers and heterodimers, including those resistant to existing inhibitors, by binding to the dimer interface
Implementation Method 2
Braftide is designed to inhibit both BRAF homodimers and heterodimers, including those resistant to existing inhibitors, by binding to the dimer interface and triggering proteasome-mediated degradation of BRAF and MEK
Data Source
AI summary
In one aspect, the invention provides a polypeptide derived from the dimer interface of BRAF, which is useful for treating various types of cancers. In certain embodiments, the polypeptide can be used to treat, prevent, and/or ameliorate a cancer such as but not limited to lung cancer.